Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for ...
Alvotech, a biotech company focused on developing biosimilar medicines, announced its inclusion in the Nasdaq Biotechnology Index (NBI) as part of the index's annual reconstitution, effective December ...
Consistent with the practice instituted earlier this year, I take a look at the institutional changes in stocks that are part of the Long-Term Growth Portfolio in Q1 2017. Part 2 will be dedicated to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback